Alnylam Pharmaceuticals, Inc. (ALNY) stock coverage started with “Buy” in note to investors by Ladenburg Thalmann Financial Services

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares rose on Thursday February 2 on lower trade volume than normal after more analysts initiated coverage on the stock.

Meanwhile, The Dow Jones Industrial Average DJIA, -0.10% fell 34 points, or 0.2%, to 19,858. The S&P 500 SPX, -0.11% lost 4 points to 2,276, a drop of 0.2%. The Nasdaq Composite Index COMP, -0.05% slid 16 points, or 0.3%, to 5,626. Among the most actively traded Nasdaq stocks was Facebook Inc FB, +0.31% which fell 0.7% a day after it reported its quarterly results.

Analysts at Ladenburg Thalmann Financial Services initiated coverage on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) stock, starting the company at Buy. The company currently has a rating of Buy on the shares. The one-year price target of $63.57 is above the opening price of $40.76, causing a fair amount of other analysts to comment on the stock recently. Looking back over the last 52 weeks, Alnylam Pharmaceuticals, Inc. stock has a high of $80.11. Analysts and brokerage firms will subsequently issue periodic updates after initiating coverage,. Changes in price targets are not unusual.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) opened at $40.76 yesterday trading between $40.04 and $40.92, and last traded at $40.60, a spike of $0.15 over the previous closing price.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) now has a market cap of 3.48B.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Average Daily Trading Volume

90,385 shares crossed the trading desk yesterday, 103 percent below the norm, out of a total float 70,877,000. lower than normal. Look for trading volume to pick up in the coming days as swing traders often use increases in trading volume to identify heavy volume accumulation or distribution by institutional investors.

However, a single day of heavy buy side trading is not enough to assert a trend. As such, market traders will continue to watch for institutional sponsorship as a signal that financial institutions are moving forward.

Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Institutional investors such as these have teams of analysts researching thousands of stocks. Thus, watching their interests is a good way to make sure you are buying the right stocks.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By identifying trends, moving averages allow traders to make those trends work in their favor and increase the number of successful trades.

Trades for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) have ranged from $31.38 – 80.11, and the stock now has a 50-day MA of $40.35 and 200-day MA of $53.39. Today’s last price is 49.32%% below the 52 week high of $80.11.

Earnings growth is a crucial factor to consider when investing in stocks and investors watch for companies that have been successful at growing their earnings at least 25% or more over the past 3 years.

DISCLOSURE: The views and opinions expressed in this article do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Latest News

Leave a Reply